Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017152044) COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/152044 International Application No.: PCT/US2017/020650
Publication Date: 08.09.2017 International Filing Date: 03.03.2017
IPC:
A61K 31/7088 (2006.01) ,A61K 35/12 (2015.01) ,A61K 35/28 (2015.01) ,A61K 39/395 (2006.01) ,A61K 45/06 (2006.01)
[IPC code unknown for A61K 31/7088][IPC code unknown for A61K 35/12][IPC code unknown for A61K 35/28][IPC code unknown for A61K 39/395][IPC code unknown for A61K 45/06]
Applicants:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386 Stanford, CA 94305-2038, US
Inventors:
BLAU, Helen, M.; US
HO, Andrew, Tri, Van; US
PALLA, Adelaida, R.; US
Agent:
HAO, Joe, C.; US
ROBERTS, Byron, N.; US
SANI, Barmak, S.; US
SHURTZ, Kenneth; US
SNYDER, Joseph, R.; US
Priority Data:
62/303,97904.03.2016US
62/348,11609.06.2016US
Title (EN) COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2
(FR) COMPOSITIONS ET MÉTHODES DE RÉGÉNÉRATION MUSCULAIRE À L'AIDE DE LA PROSTAGLANDINE E2
Abstract:
(EN) Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
(FR) L'invention concerne des compositions, des méthodes et des kits de lutte contre la prolifération de cellules musculaires, par exposition des cellules musculaires à un composé de prostaglandine E2 (PGE2) ou à un composé qui active la signalisation de PGE2. L'invention concerne également des méthodes de régénération d'un muscle chez un sujet souffrant d'une amyotrophie, d'une dystrophie et/ou d'une lésion, par administration d'un composé de PGE2 seul ou combiné à des cellules musculaires isolées. Le composé de PGE2, combiné aux cellules musculaires isolées, peut être administré de manière prophylactique pour prévenir une maladie ou une affection musculaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)